Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05338775
Title A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Acronym TRIMM-3
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU


No variant requirements are available.